African Americans more likely to exhibit negative perceptions of cancer-related clinical trials
the ONA take:
According to new findings that will be presented at the 2015 American Society of Clinical Oncology Annual Meeting in Chicago, Illinois, researchers from Fox Chase Cancer Center and Temple University in Philadelphia, Pennsylvania, have found that African Americans are more likely to display negative perceptions of participating in cancer-related clinical trials.
For the study, researchers identified 41 African Americans with an average age of 60 years. Of those, 54% had no enrolled in a clinical trial within the past 9 months.
Researchers found that non-participants believed that a clinical trial would make them sicker, that important information would be withheld from them, and that no one discussed clinical trial participation with them.
Those who participated in clinical trials felt their doctor had provided enough information in order to make an informed decisions about clinical trial participation and that trials offered the best possible treatment for their disease.
The findings suggest that African American patients with cancer should received detailed information regarding clinical trial participation and their treatment options.
African Americans are more likely to display negative perceptions of participating in cancer-related clinical trials.
Sign Up for Free e-newsletters
- Managing Chemo Brain in Pediatric Survivors of Childhood Cancer
- A Witness to Letting Go: Nursing Care at the End of Life
- CHEMO-SUPPORT: A Nursing Intervention to Relieve Chemotherapy Symptom Burden
- Intervention Improves Breast Cancer Survivors' Memory Contentment
- Excretion of Volatile Organic Compounds Higher in AYAs Using Vaping Products
- Various Aspects of Palliative Care Focus Associated With Different Outcomes In Cancer
- Cost vs Benefits: The Controversy Over Proton Beam Radiotherapy
- Patient Expectations at Odds With Actual Outcomes for Radiotherapy in Breast Cancer
- Patients Desire More Online Tools and Access
- Metformin Plus Ruxolitinib: A Potential Therapeutic Alternative for Myeloproliferative Neoplasms
- Patients With Head and Neck Cancer Have Greater Chance of Being Prescribed Opioids
- Medical Terms in Patient Education: Using the Confusing to Explain the Complicated
- Bedside Assessment Tool Improves Worst Pain in Patients With Cancer
- Androgen-Deprivation Therapy for Prostate Cancer May Cause Nocturia, Sleep Disturbance
- USPSTF Rates Ovarian Cancer Screening a D for Asymptomatic, Low-Risk Women
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|